Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Pharma Mar SA ( (ES:PHM) ).
Pharma Mar SA has reported on its recent share buy-back program activities conducted between May 12 and May 16, 2025. This initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value, reflecting a proactive approach to managing its market presence.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA operates in the pharmaceutical industry, focusing on the development and commercialization of marine-derived drugs. The company is known for its work in oncology and has a significant presence in the global market for cancer treatments.
YTD Price Performance: -1.63%
Average Trading Volume: 59,625
Technical Sentiment Signal: Buy
Current Market Cap: €1.41B
For detailed information about PHM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue